Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, announced that its strategic partner, Arctic Vision, a China-based biotech company concentrated on innovative ophthalmic therapies, enrolled the first patient in its Phase 3 clinical trial of ARVN003 (MicroLine) for presbyopia. This marks the first time that a clinical trial has been approved in China to examine a pharmacologic treatment for presbyopia.
In August 2020, Arctic Vision obtained from Eyenovia an exclusive license for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea. The exclusive license agreement also included Eyenovia’s development-stage candidate for pediatric progressive myopia, MicroPine. Subsequent to this original agreement, Arctic Vision also licensed Eyenovia’s development-stage candidate for pharmacological mydriasis, MydCombi. Eyenovia is currently preparing a New Drug Application (NDA) to acquire marketing approval for MydCombi in the U.S.
Read more here